Schein, Jeff
Cloutier, Martin
Gauthier-Loiselle, Marjolaine
Bungay, Rebecca
Chen, Kathleen
Chan, Deborah
Guerin, Annie
Childress, Ann
Article History
Received: 13 October 2023
Accepted: 17 June 2024
First Online: 8 July 2024
Declarations
:
: Data analyzed in this study are de-identified and comply with the patient requirements of the Health Insurance Portability and Accountability Act (HIPAA); therefore, no review by an institutional review board nor informed consent was required per Title 45 of CFR, Part 46.101(b)(4) [].
: Not applicable.
: JS is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. MC, MGL, RB, KC, DC, and AG are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Otsuka Pharmaceutical Development & Commercialization, Inc. AC received research support from Allergan, Takeda/Shire, Emalex, Akili, Ironshore, Arbor, Aevi Genomic Medicine, Neos Therapeutics, Otsuka, Pfizer, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, and the U.S. Food and Drug Administration; was on the advisory board of Takeda/Shire, Akili, Arbor, Cingulate, Ironshore, Neos Therapeutics, Otsuka, Pfizer, Purdue, Adlon, Rhodes, Sunovion, Tris, Supernus, and Corium; received consulting fees from Arbor, Ironshore, Neos Therapeutics, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, Corium, Jazz, Tulex Pharma, and Lumos Pharma; received speaker fees from Takeda/Shire, Arbor, Ironshore, Neos Therapeutics, Pfizer, Tris, and Supernus; and received writing support from Takeda /Shire, Arbor, Ironshore, Neos Therapeutics, Pfizer, Purdue, Rhodes, Sunovion, and Tris.